AI news
1. Eli Lilly and Isomorphic Labs Advance First Fully AI--Designed Drug to Phase III Trials
Date: July 27, 2026
Eli Lilly and Alphabet’s Isomorphic Labs have announced that ISO--101, a drug candidate for Alzheimer’s disease designed entirely through generative AI, has been cleared for Phase III clinical trials. The AI--driven discovery process shortened the traditional five--year development timeline to approximately 18 months. By utilizing advanced predictive protein--folding and multi--target optimization, the platform identified a molecule with significantly higher blood--brain barrier permeability than existing treatments. This milestone validates the economic and clinical potential of AI in reversing the "Eroom’s Law" trend in pharmaceutical R&D.
| Metric | Detail |
|---|---|
| Drug Candidate | ISO--101 |
| Development Time | 18 Months |
| Technology | Generative Protein--Folding AI |
| Regulatory Status | Phase III Clearance |